JP2026048706A5 - - Google Patents

Info

Publication number
JP2026048706A5
JP2026048706A5 JP2025206113A JP2025206113A JP2026048706A5 JP 2026048706 A5 JP2026048706 A5 JP 2026048706A5 JP 2025206113 A JP2025206113 A JP 2025206113A JP 2025206113 A JP2025206113 A JP 2025206113A JP 2026048706 A5 JP2026048706 A5 JP 2026048706A5
Authority
JP
Japan
Prior art keywords
amino acid
agonist
polypeptide chain
acid sequence
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025206113A
Other languages
English (en)
Japanese (ja)
Other versions
JP2026048706A (ja
Filing date
Publication date
Priority claimed from PCT/US2021/031806 external-priority patent/WO2021231447A1/en
Application filed filed Critical
Publication of JP2026048706A publication Critical patent/JP2026048706A/ja
Publication of JP2026048706A5 publication Critical patent/JP2026048706A5/ja
Pending legal-status Critical Current

Links

JP2025206113A 2020-05-12 2025-11-27 新規なil10アゴニストおよびその使用方法 Pending JP2026048706A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063023703P 2020-05-12 2020-05-12
US63/023,703 2020-05-12
PCT/US2021/031806 WO2021231447A1 (en) 2020-05-12 2021-05-11 Novel il10 agonists and methods of use thereof
JP2022568853A JP7827640B2 (ja) 2020-05-12 2021-05-11 新規なil10アゴニストを含む治療剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022568853A Division JP7827640B2 (ja) 2020-05-12 2021-05-11 新規なil10アゴニストを含む治療剤

Publications (2)

Publication Number Publication Date
JP2026048706A JP2026048706A (ja) 2026-03-17
JP2026048706A5 true JP2026048706A5 (enExample) 2026-05-21

Family

ID=76181307

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022568853A Active JP7827640B2 (ja) 2020-05-12 2021-05-11 新規なil10アゴニストを含む治療剤
JP2025206113A Pending JP2026048706A (ja) 2020-05-12 2025-11-27 新規なil10アゴニストおよびその使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022568853A Active JP7827640B2 (ja) 2020-05-12 2021-05-11 新規なil10アゴニストを含む治療剤

Country Status (12)

Country Link
US (3) US11673930B2 (enExample)
EP (1) EP4149963A1 (enExample)
JP (2) JP7827640B2 (enExample)
KR (1) KR20230009430A (enExample)
CN (1) CN115667290A (enExample)
AU (1) AU2021270563A1 (enExample)
BR (1) BR112022022899A2 (enExample)
CA (1) CA3183151A1 (enExample)
IL (1) IL298007A (enExample)
MX (1) MX2022014239A (enExample)
WO (1) WO2021231447A1 (enExample)
ZA (1) ZA202210918B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4719458A2 (en) * 2023-06-01 2026-04-08 Synthekine, Inc. Il10 inverted monomers

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
ES2102007T3 (es) 1992-01-23 1997-07-16 Merck Patent Gmbh Proteinas de fusion de fragmentos de anticuerpo monomeras y dimeras.
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6410008B1 (en) 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
GB9824437D0 (en) 1998-11-06 1999-01-06 Ylo Herttuala Seppo Gene therapy
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
EP2284192A3 (en) 2002-11-08 2011-07-20 Ablynx N.V. Camelidae antibodies for sublingual administration
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
HUE026278T2 (en) 2003-07-01 2016-05-30 Ucb Biopharma Sprl Modified Fab antibody fragments
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
WO2005049094A1 (en) 2003-11-13 2005-06-02 Advantagene, Inc. A mixed complementary viral vector for gene therapy
CA2577082A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
US7939056B2 (en) 2005-11-14 2011-05-10 The Brigham And Women's Hospital, Inc. Interleukin-10 compositions for the treatment of adenocarcinomas
AR059193A1 (es) * 2006-01-31 2008-03-12 Bayer Schering Pharma Ag Modulacion de la actividad de mdl-1 para el tratamiento de enfermedades inflamatorias
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
WO2008025032A1 (en) * 2006-08-25 2008-02-28 Zymogenetics, Inc. Soluble il-27 receptor
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
LT2975051T (lt) 2009-06-26 2021-07-12 Regeneron Pharmaceuticals, Inc. Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
WO2012045334A1 (en) 2010-10-05 2012-04-12 Synthon Bv Biologically active il-10 fusion proteins
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
BR112015002085A2 (pt) * 2012-08-08 2017-12-19 Roche Glycart Ag proteína, polinucleotídeo, vetor, célula hospedeira, método para produzir a proteína, composição farmacêutica, uso da proteína, método de tratamento e invenção
MX385344B (es) 2012-11-28 2025-03-18 Zymeworks Bc Inc Pares de cadena pesada-cadena ligera de inmunoglobulina modificados genéticamente y usos de estos.
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
ES2821753T3 (es) 2013-03-15 2021-04-27 Lilly Co Eli Procedimientos de producción de Fab y de anticuerpos biespecíficos
CN105209054A (zh) 2013-04-18 2015-12-30 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
US11413332B2 (en) 2013-11-11 2022-08-16 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
EP3102594A1 (en) 2014-02-06 2016-12-14 F. Hoffmann-La Roche AG Interleukine 10 immunoconjugates
JP6675394B2 (ja) 2014-10-22 2020-04-01 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害の治療のためにインターロイキン−10を使用する方法
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
WO2016100788A1 (en) * 2014-12-19 2016-06-23 Alkermes, Inc. Single chain fc fusion proteins
WO2016161010A2 (en) 2015-03-30 2016-10-06 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
US20160361415A1 (en) 2015-05-28 2016-12-15 Armo Biosciences, Inc. Methods of Using Interleukin-10 for Treating Diseases and Disorders
WO2017087768A1 (en) 2015-11-18 2017-05-26 Duke University Targeted delivery of interleukin-10 to tumor infiltrating lymphocytes
EP3448260A4 (en) * 2016-04-27 2019-10-09 Immunomedics, Inc. EFFICACY OF ANTI-TROP-2 SN-38 ANTIBODY CONJUGATES FOR THE THERAPY OF REZIDIVATED / REFRACTORY TUMORS AGAINST CHECKPOINT INHIBITORS
WO2017210684A1 (en) 2016-06-03 2017-12-07 New York University Methods and reagents for modulating macrophage phenotype
CA3026393C (en) 2016-06-22 2023-03-14 Alkermes, Inc. Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
EP3576789B1 (en) 2017-02-01 2024-12-11 Zhejiang Shimai Pharmaceutical Co., Ltd. MONOMERIC HUMAN IgG1 Fc AND BISPECIFIC ANTIBODIES
US20190070262A1 (en) * 2017-09-06 2019-03-07 Yale University Interleukin-18 variants and methods of use
US20200353050A1 (en) * 2017-11-10 2020-11-12 Armo Biosciences, Inc. Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitors
WO2019152344A1 (en) 2018-01-30 2019-08-08 University Of Louisville Research Foundation, Inc. Compositions and methods for treating inflammation and cancer
CN111867630B (zh) * 2018-06-17 2023-10-13 上海健信生物医药科技有限公司 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
CN111989340B (zh) * 2018-11-18 2025-07-15 杭州博虎生物科技有限公司 一种重组人白细胞介素-10融合蛋白及其应用
WO2020172631A2 (en) * 2019-02-21 2020-08-27 Xencor, Inc. Untargeted and targeted il-10 fc-fusion proteins
CN113692416B (zh) * 2019-03-25 2024-11-08 施慧达药业集团(吉林)有限公司 蛋白质异二聚体及其用途
EP3955955B1 (en) * 2019-04-19 2025-02-26 Synerkine Pharma B.V. A fusion protein comprising il13
EP3795583A1 (en) * 2019-09-19 2021-03-24 Ecole Polytechnique Federale de Lausanne (EPFL) Il10/fc fusion proteins useful as enhancers of immunotherapies
KR20220139915A (ko) * 2020-02-06 2022-10-17 브리스톨-마이어스 스큅 컴퍼니 Il-10 및 그의 용도

Similar Documents

Publication Publication Date Title
Yu et al. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
US11905322B2 (en) Engineered PD-1 variants
JP2023518518A5 (enExample)
JP2021502810A5 (enExample)
US7919083B2 (en) Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
US20220041724A1 (en) Plasmid constructs for treating cancer and methods of use
JP2020508691A5 (enExample)
JP2022512043A5 (enExample)
Kufer et al. Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer
EP4019536A1 (en) Immunocytokine, preparation for same, and uses thereof
JP2024528665A5 (enExample)
WO2019057180A1 (en) PROTEIN HETÉRODIMÈRE AND USE THEREOF
JP2024517871A5 (enExample)
CN118695868A (zh) 包含il-10的双细胞因子融合蛋白与过继细胞疗法或双特异性t细胞衔接器用于治疗癌症
JP2022553292A5 (enExample)
JP2023548556A5 (enExample)
CN107226866A (zh) 一种抗cd24人源化抗体融合蛋白
CN119997974A (zh) 一种异源二聚体融合蛋白及其应用
JP2023525555A5 (enExample)
JP2022535816A5 (enExample)
CN102924579B (zh) 一种具有提高人nk及nkt细胞杀伤肿瘤细胞活性的多肽及其应用
CN117986383A (zh) 融合蛋白及其应用
JP7827646B2 (ja) がん免疫療法に対する応答性を決定する方法
CN116655804A (zh) 一种用于激活嵌合抗原受体效应细胞的中间模块分子及其应用
CN115154598A (zh) 一种抗pd-1/vegf双特异性抗体液体制剂